Journal of Medicinal Chemistry · 2012 · 37 citations · 40 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryEnzymologyAntibacterial PharmacologyAntiparasitic PharmacologyDrug-metabolizing EnzymesEnzyme InhibitionAntimalarial AgentsAntimalarial ChemotherapyAntimalarial Drug DevelopmentHydroxamic Acid BioisosteresLipophilic ProdrugsNon-mevalonate PathwayPlasmodium FalciparumTreatment Of Malaria
Specific inhibition of enzymes of the non-mevalonate pathway is a promising strategy for the development of novel antiplasmodial drugs. α-Aryl-substituted β-oxa isosteres of fosmidomycin with a reverse orientation of the hydroxamic acid group were synthesized and evaluated for their inhibitory activity against recombinant 1-deoxy-d-xylulose 5-phosphate reductoisomerase (IspC) of Plasmodium falciparum and for their in vitro antiplasmodial activity against chloroquine-sensitive and resistant strains of P. falciparum . The most active derivative inhibits IspC protein of P. falciparum (PfIspC) with an IC(50) value of 12 nM and shows potent in vitro antiplasmodial activity. In addition, lipophilic ester prodrugs demonstrated improved P. falciparum growth inhibition in vitro.
40
Numerical recipes: the art of scientific computing
W. H. Press, Brian P. Flannery, Saul A. Teukolsky et al. · Analytica Chimica Acta · 1987 · 3.3K citations
Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs
Hassan Jomaa, Jochen Wiesner, Silke Sanderbrand et al. · Science · 1999 · 1.2K citations